SALUS is the first U.S. clinical trial of the Direct Flow Medical Transcathether Aortic Valve System, and will seek to evaluate how well the test valve can be delivered and its effectiveness once it is in use. Northwestern’s enrollment is the first in Illinois and the fourth institute in the country to enroll subjects.
“Aortic stenosis is a condition that commonly affects older individuals. The leaflets of the aortic valve become thick and calcified and ultimately can limit the ability of blood from being pumped out of the heart,” said James D. Flaherty, MD, Northwestern Medicine cardiologist and Northwestern’s principal investigator for SALUS. “When the narrowing becomes severe, patients develop symptoms such as shortness of breath, fatigue, lightheadedness and chest pain. If uncorrected, their life expectancy is also significantly shortened.”
Open-heart surgery has been the gold standard treatment for aortic stenosis since the 1960’s. However, many patients are considered high-risk or inoperable for traditional heart surgery. Transcatheter Aortic Valve Replacement (TAVR) is a technique to insert a new aortic valve through catheters instead of open heart surgery. The only transcatheter heart valve that is commercially available in the United States requires larger catheters than the study valve, sits within a metal ring, and cannot be repositioned or replaced once it is released from the catheter.
“Aortic valve replacement is a life saving procedure for patients with severe symptomatic aortic stenosis. TAVR, which is done without the need of a cardiopulmonary bypass machine, may also prove to be life saving in patients who are not eligible for cardiac surgery,” said Flaherty, who is also an Associate Professor of Medicine in Interventional Cardiology at Northwestern University’s Feinberg School of Medicine. “This study valve is inserted through smaller catheters and its unique design allows it to be repositioned or replaced until the Heart Team is satisfied that it is in the optimal position. It is also expected that this design will prove to cut down or even eliminate any leaking, called aortic regurgitation, around the implanted valve.”
Instead of using a metal stent frame, the Direct Flow Medical Transcathether Aortic Valve System’s polymer support structure uses an inflatable, conformable cuff that has the ability to provide a better seal and prevent leaking. The study valve is composed of two inflatable rings at each end that are connected by multiple inflatable bars, all of which are covered with a polyester fabric sleeve and surround the heart valve itself. During a procedure, the study valve’s inflatable rings and connecting bars are filled with a liquid plastic polymer that hardens to a solid after it has been fitted to further help prevent leakage around the valve.
The SALUS clinical trial seeks to enroll up to 30 participants and its expected duration is five and half years, when the last participant finishes his or her follow-up period. To learn more about the SALUS trial, please call the Bluhm Cardiovascular Institute Clinical Trials Unit (CTU) at 312-695-1806 or email firstname.lastname@example.org.
Northwestern Medicine is the shared vision that joins Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine in a collaborative effort to transform medicine through quality healthcare, academic excellence and scientific discovery.
For more information on Northwestern’s Bluhm Cardiovascular Institute, visit www.heart.nmh.org. To schedule an appointment, please call 312-NM-HEART (664-3278).
Senior Media Relations Associate